Seres Therapeutics Future Growth

Future criteria checks 2/6

Seres Therapeutics is forecast to grow earnings and revenue by 38.4% and 56.5% per annum respectively. EPS is expected to grow by 48.8% per annum. Return on equity is forecast to be -313% in 3 years.

Key information

38.4%

Earnings growth rate

48.8%

EPS growth rate

Biotechs earnings growth	35.3%
Revenue growth rate	56.5%
Future return on equity	-313.0%
Analyst coverage	Good
Last updated	12 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:1S9 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	74	-67	N/A	-134	5
12/31/2025	11	-109	N/A	-97	7
12/31/2024	22	-102	N/A	42	7
6/30/2024	0	-162	-185	-182	N/A
3/31/2024	127	-83	-80	-76	N/A
12/31/2023	126	-114	-125	-117	N/A
9/30/2023	127	-141	-133	-123	N/A
6/30/2023	130	-153	-133	-123	N/A
3/31/2023	5	-265	-250	-239	N/A
12/31/2022	7	-250	-239	-229	N/A
9/30/2022	13	-231	-236	-228	N/A
6/30/2022	137	-103	-51	-40	N/A
3/31/2022	141	-87	-41	-30	N/A
12/31/2021	145	-66	-3	7	N/A
9/30/2021	155	-34	32	41	N/A
6/30/2021	30	-132	-117	-113	N/A
3/31/2021	31	-105	-101	-99	N/A
12/31/2020	33	-89	-94	-94	N/A
9/30/2020	23	-90	-90	-90	N/A
6/30/2020	29	-76	-83	-82	N/A
3/31/2020	35	-66	-69	-68	N/A
12/31/2019	35	-70	-78	-77	N/A
9/30/2019	38	-73	-50	-50	N/A
6/30/2019	40	-78	-56	-55	N/A
3/31/2019	32	-95	-70	-68	N/A
12/31/2018	28	-99	-65	-63	N/A
9/30/2018	21	-107	-99	-96	N/A
6/30/2018	35	-92	-79	-77	N/A
3/31/2018	33	-92	N/A	-77	N/A
12/31/2017	32	-89	N/A	-76	N/A
9/30/2017	32	-86	N/A	-76	N/A
6/30/2017	22	-97	N/A	-83	N/A
3/31/2017	22	-97	N/A	-83	N/A
12/31/2016	22	-92	N/A	44	N/A
9/30/2016	19	-86	N/A	53	N/A
6/30/2016	6	-82	N/A	53	N/A
3/31/2016	3	-67	N/A	69	N/A
12/31/2015	N/A	-55	N/A	-41	N/A
9/30/2015	N/A	-44	N/A	-33	N/A
6/30/2015	N/A	-34	N/A	-25	N/A
3/31/2015	N/A	-24	N/A	-17	N/A
12/31/2014	N/A	-18	N/A	-10	N/A
9/30/2014	N/A	-12	N/A	-8	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1S9 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1S9 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1S9 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1S9's revenue (56.5% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: 1S9's revenue (56.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1S9 is forecast to be unprofitable in 3 years.

Seres Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

Seres Therapeutics, Inc. Announces Topline Clinical Data from Cohort 2 of its SER-155 Phase 1b Placebo-Controlled Study in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

First half 2024 earnings released: US$0.49 loss per share (vs US$0.20 loss in 1H 2023)

Seres Therapeutics, Inc. announced that it expects to receive $15.000001 million in funding from Société des Produits Nestlé S.A.

Seres Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic

New minor risk - Market cap size

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)

Seres Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

New minor risk - Financial position

Full year 2023 earnings released: US$0.89 loss per share (vs US$2.32 loss in FY 2022)

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

New major risk - Negative shareholders equity

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.36 (vs US$0.70 loss in 2Q 2022)

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Full year 2022 earnings released: US$2.32 loss per share (vs US$0.71 loss in FY 2021)

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Third quarter 2022 earnings released: US$0.49 loss per share (vs US$0.74 profit in 3Q 2021)

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Second quarter 2022 earnings released: US$0.70 loss per share (vs US$0.53 loss in 2Q 2021)

Seres Therapeutics, Inc. Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection At the Digestive Disease Week (Ddw) Annual Meeting

First quarter 2022 earnings released: US$0.61 loss per share (vs US$0.39 loss in 1Q 2021)

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Seres Therapeutics, Inc. Announces the Publication in the New England Journal of Medicine of Data from Its Phase 3 ECOSPOR III study evaluating SER-109

Seres Therapeutics, Inc. Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

Seres Therapeutics Announces First Patient Enrolled in Phase 1B Study of SER-155

Third quarter 2021 earnings released: EPS US$0.74 (vs US$0.36 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.53 loss per share (vs US$0.28 loss in 2Q 2020)

Seres Therapeutics, Inc. Announces Topline Results from the Phase 2B ECO-RESET Study Evaluating SER-287 in Patients with Mild-To-Moderate Ulcerative Colitis

Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from Russell 3000E Index

Seres Therapeutics Presents Research from Its Early-Stage Microbiome Therapeutic Oncology Programs At the 2021 American Society of Clinical Oncology (Asco) Annual Meeting

Seres Therapeutics Announces U.S. Food and Drug Administration Clearance of Investigational New Drug for SER-155

Seres Therapeutics, Inc. Presents Data Across Its Broad Microbiome Pipeline Including New 24-Week Data from Ser-109 Phase 3 Ecospor III Study in Recurrent C. Difficile Infection At Digestive Disease Week 2021

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.28 loss in 1Q 2020)

Seres Therapeutics, Inc. Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma

Full year 2020 earnings released: US$1.12 loss per share (vs US$1.24 loss in FY 2019)

Revenue beats expectations

Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis

New 90-day low: €17.40

New 90-day low: €18.80

Seres Therapeutics, Inc. Therapeutics to Present SER-109 Phase 3 Mechanistic Data At Keystone Symposium

Seres Therapeutics, Inc. Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology

New 90-day low: €19.00

New 90-day low: €19.40

Revenue misses expectations

Third quarter 2020 earnings released: US$0.36 loss per share

New 90-day high: €28.80

Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

Seres Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day high: €27.80

Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting

New 90-day high: €23.60

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts